Shots:
- Trial assessed eneboparatide (ENB; QD, SC) vs PBO for 24wks. in 202 adults with HypoPT on active vitamin D & oral Ca supplements; Pts then continued ENB (ENB/ENB) or switched from PBO to ENB (PBO/ENB) in a 28wk. OLE
- Trial met its composite 1EP, with 31.1% pts achieving normalized albumin-adjusted sCa levels & independence from supplements at Wk. 24 vs 5.9% (41/132 vs 4/68); immunogenicity was observed in most pts, sCa was controlled with supplements & ENB up-titration.
- ENB also met all key 2EPs at wk. 24, incl. normalization of uCa excretion in hypercalciuria pts in 56.6% vs 20% (43/76 vs 9/45), plus it improved PROs; benefits were maintained in ENB/ENB group through wk. 52, with preserved bone health & no clinically significant BMD reduction
Ref: AstraZeneca | Image: AstraZeneca | Press Release
Related News: AstraZeneca Reports FDA Approval of Saphnelo for Systemic Lupus Erythematosus (SLE)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
